ER

Eric Rose

Mesoblast Limited | Non-Executive Director
Dr. Rose is a physician scientist with focus on clinical investigation, drug discovery, biodefense, and health policy. As heart surgeon and scientist, Dr. Rose led the Columbia Presbyterian heart transplantation program from 1982 through 1992 and made history in 1984 when he performed the first pediatric heart transplant. From 1994 through 2007, he served as Chairman of Columbia University's Department of Surgery and Surgeon-in-Chief of Columbia Presbyterian Medical Center in New York. During this time his leadership of the NIH supported program Randomized Evaluation of Mechanical Circulatory Support in Heart Failure (REMATCH) resulted in the first FDA approval of an implantable left ventricular assist device for long term circulatory support, spawning an entire new industry. From 2007-2011, Dr. Rose served on the National Biodefense Scientific Board which advises the United States Health and Human Services Secretary on biodefense, influenza, and emerging diseases. In 2007 he was appointed Chairman and CEO of SIGA Technologies where he oversaw development of the first antipoxviral drug approved in the United States, TPOXX for the treatment of smallpox. Dr. Rose played a role in obtaining FDA approval of the drug in 2019, and he was responsible for securing contracts with BARDA under which the US Government has procured 1.7 million courses of TPOXX for more than US$1billion into the Strategic National Stockpile (SNS). Dr. Rose's tenure on the ABIOMED board ended in December 2022 with the sale of the company to Johnson & Johnson for $17.7 billion. Former directorships of listed public companies within the last 3 years: Chairman, SIGA Technologies, Inc. (2017 - 2021), Non-executive Director, ABIOMED, Inc. which was acquired by Johnson & Johnson. (2007 - 2012, 2014 - 2022

Company and Role

Company
Title
Tenure
Since
MSB
Mesoblast Limited
  • Non-Executive Director
11yrs, 9mthApr 2013

Holding

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
MSB
Mesoblast Limited
16/01/25411,62071,4726,596,953N/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
MSB
Mesoblast Limited
16/01/25
Buy
30,310$16.701$506,214On-market trade
MSB
Mesoblast Limited
09/01/25
Issued
2,266,188$2.810$6,367,988Issue of options
MSB
Mesoblast Limited
08/05/24
Buy
19,734$7.662$151,207On-market trade
MSB
Mesoblast Limited
30/04/24
Buy
21,428$6.642$142,318On-market trade
MSB
Mesoblast Limited
10/01/24
Issued
1,960,765$0.285$558,818Issue of options